header logo image


Page 39«..1020..38394041..5060..»

Archive for the ‘Immune System’ Category

What is the adenovirus? – Home – WSFX

Sunday, January 26th, 2020

Adenoviruses can result in colds, bronchitis, respiratory infections, croup (barking cough), ear infections, pink eye, pneumonia, stomach infections, UTIs, and in rare cases, meningitis.(iStock)

Dear Dr. Manny,

My daughters keep getting sick in elementary school. They always have colds and fevers. Recently the school put out a warning about adenovirus, and I was wondering: What is the adenovirus? What kills adenovirus on the surface? How long is the disease contagious?

Thanks for your question.

Adenoviruses are viruses that affect the lining of the eyes, airways, lungs, intestines, urinary tract, and the nervous system. They cause coughs, pinkeye, fevers, diarrhea, and sore throats. Typically children catch them more frequently than adults.

IS A CANKER SORE CAUSING YOUR MOUTH PAIN?

These infections are usually somewhat mild and go away on their own. But if someone has a weak immune systemor a pre-existing condition, these infections can be dangerous. They are very contagious, and spread through droplets from a cough or sneeze.

Adenoviruses can result in colds, bronchitis, respiratory infections, croup (barking cough), ear infections, pink eye, pneumonia, stomach infections, UTIs, and in rare cases, meningitis.

WHAT IS DRY FASTING?

You cant treat these infections with antibiotics, because they are viral, not bacterial, so prevention is key.

Hand sanitizers do not prevent the spread of adenoviruses. Rather, its important to wash your hands with soap and water. Dont rub your eyes or your nose in public places. Clean surfaces like sinks, counters, floors, doorknobs, cell phones, and commonly used toys with cleaner and water.

CLICK HERE TO GET THE FOX NEWS APP

The virus stays contagious long after someone recovers from an infection, and will infect any person with a low immunity.

Do you have a health question for Dr. Manny? Email us atAskDrManny@FoxNews.com

More:
What is the adenovirus? - Home - WSFX

Read More...

Pneumonia: what are the symptoms and who is at risk? – The Guardian

Sunday, January 26th, 2020

What is pneumonia?

Pneumonia is an inflammation of the tissue in one or both lungs, usually caused by a bacterial infection. It causes tiny air sacs at the end of the breathing tubes in the lungs to fill up with fluid. The body sends white blood cells to the lungs to try to fight the infection, which helps kill the germs but can also make it harder for the lungs to pass oxygen into the bloodstream.

People with a weaker immune system, whether because of age, illness or disease. Babies, infants and older people, as well as smokers and heavy drinkers, are at higher risk. People with other health conditions, including cancer, long-term heart, lung and kidney diseases and diabetes are also at increased risk, as are those whose immune system has been weakened through chemotherapy or certain medications or because they have HIV/Aids.

They are typically similar to a flu or chest infection so would include a high temperature or fever, sweating, shivering and a cough that brings up phlegm, as well as a loss of appetite. Signs that it is more serious include breathing quickly and feeling confused or disoriented, which is mostly observed in older people. A sharp pain in the side of the chest, which becomes worse when taking a deep breath, usually means that pleurisy an inflammation of the thin outer covering of the lung has developed.

The vast majority of people will recover from pneumonia and return to good health. In milder cases it could involve a few days or a week of being unwell and then a steady return to normality. But in severe cases it can take six months or even longer to clear and it is a leading cause of death among old and seriously ill people. In a person in poor health or with a weak immune system, untreated pneumonia can cause oxygen levels to fall so far that body tissue is starved particularly in the heart and brain of the oxygen it needs to function.

In a healthy person, rest and plenty of water plus antibiotics if it is bacterial can suffice as their natural defences kick in. If symptoms are severe (more common with bacterial infections), hospital treatment will be needed. Patients will receive antibiotics and fluids through a drip, and may need oxygen to help them breathe. In very serious cases patients may be put on a ventilator.

Read the rest here:
Pneumonia: what are the symptoms and who is at risk? - The Guardian

Read More...

Scientists find immune cells that fight tumours from within – The Straits Times

Sunday, January 26th, 2020

TOKYO Lurking deep inside some tumours are "factories" full of immune cells that help the body fight a rearguard action against cancer and are key to helping some patients recover, new research has shown.

In recent years, doctors have turned to a new treatment for cancer - immunotherapy - that works by leveraging the body's immune system to fight tumours.

The technique has largely focused on white blood cells called T-cells, which are "trained" to recognise and attack cancer cells.

But the innovative treatment works well for only around 20 per cent of patients, so researchers have been trying to understand why some people respond better than others.

Three papers published last Thursday in the journal Nature point the way, identifying a key formation inside some tumours: tertiary lymphoid structures (TLS).

TLS function like factories or schools for immune cells that help the body fight cancer, said Professor Wolf Fridman, a professor emeritus of immunology at the Cordeliers Research Centre of the Paris Descartes University medical school, who led one of the studies.

He said the cells need to be educated in "schools" - the TLS - where they learn to recognise and attack cancer cells.

Key to the findings is that T-cells are far from the only immune cells capable of taking the fight to cancer. Researchers found the TLS were full of B-cells, a kind of immune cell that produces antibodies.

"We have been T-cell addicts for 15 years in cancer," Prof Fridman said. "We analysed these sarcomas to see what groups they had and what's striking is that these B-cells appeared."

Dr Beth Helmink, a fellow in surgical oncology at the University of Texas' MD Anderson Cancer Centre, who worked on a second study, said the research had changed perceptions of the role of B-cells in immunotherapy.

"Through these studies, we find that B-cells are not just innocent bystanders, but are themselves contributing in a meaningful way to the anti-tumour immune response," she said in a statement from the centre.

The discovery is a surprise, as an abundance of B-cells in cancer patients has sometimes been seen as a marker for poor prognosis.

But the studies found patients with high levels of B-cells inside TLS in their tumours were more likely to respond well to immunotherapy.

Dr Louisa James, a lecturer in immunology at Barts and the London School of Medicine and Dentistry, Queen Mary University of London, said: "This series of studies is exciting because (it represents) real progress in the treatment of different types of cancer."

Dr James, who was not involved in the studies, added: "In the short term, these results provide a new tool to help predict which patients are likely to benefit from treatment with immunotherapy and may also pave the way for improved treatments in the future."

There are still many unanswered questions, including why TLS form in some tumours and not others.

While it now seems clear that B-cells inside the structures play a key role in the success of immunotherapy, scientists are not sure precisely how.

It may be that the B-cells are on the front lines, producing antibodies that attack cancer cells efficiently - or they may be bolstering T-cells, or perhaps even doing both.

And not all TLS are created equal: The researchers found three categories, but only one type was "mature" enough to churn out cancer-fighting immune cells.

The research opens up promising new avenues, the authors said.

Initially, the findings could help doctors screen patients to see which of them are most likely to respond well to immunotherapy.

It could eventually mean more patients are successfully treated with the technique, said Professor Goran Jonsson, a professor of oncology and pathology at Lund University in Sweden, who worked on a third study.

"If we come up with a treatment that could enhance TLS formation, we could combine this with current immunotherapy regimens," he said. "Most likely, this would lead to more patients responding to immunotherapy."

AGENCE FRANCE-PRESSE

Read more here:
Scientists find immune cells that fight tumours from within - The Straits Times

Read More...

Follow the Right Path: A Traditional Vaccine Schedule – University of Michigan Health System News

Sunday, January 26th, 2020

Once-forgotten diseases have returned to the forefront of everyones attention after outbreaks like the recent Measles cases.

Unvaccinated children are around 25 times more likely to get contagious diseases like Measles, according to the Michigan Department of Health and Human Services.

And unfortunately, unvaccinated children make up a large proportion of children in Michigan. According to I Vaccinate, only 59% of Michigan toddlers are up to date on all of their recommended vaccines.

LISTEN UP: Add theMichigan Medicine News Breakto your Alexa-enabled device, orsubscribe to our daily updates oniTunes,Google PlayandStitcher.

On a larger scale, the World Health Organization named vaccine hesitancy one of the top 10 threats to global health in 2019.

SEE ALSO: Whats Causing the Latest Measles Outbreak?

Misconceptions about the recommended vaccine schedule, or vaccines in general, have led parents to opt out or delay vaccines, putting their children and others at risk of preventable diseases, says Aarti Raheja, M.D., a pediatrician at C.S. Mott Childrens Hospital.

Some parents worry combination vaccines may harm their baby or overwhelm their immune system. This causes parents to delay certain vaccines or follow an alternative, or non-standard vaccine schedule.

The CDC refers to the alternative schedule as non-standard as opposed to alternative, which is how I address it with families because there isnt an alternative, says Raheja. No research has been done on non-standard schedules, so we dont know if they are safe or if a child would be protected.

The 2019 recommended childhood and adolescent immunization schedules have been approved by the American Academy of Pediatrics, Centers for Disease Control and Prevention (CDC) and the American Academy of Family Physicians.

Raheja adds: The recommended vaccine schedule is the only evidenced-based schedule that has been researched for safety and efficacy. It provides all the necessary protection that can be given to children with the least amount of risk.

Vaccines are added to the schedule based on when an infant is likely to be most susceptible to the disease. Administering vaccines at scheduled intervals provides the broadest immunologic protection to children when theyre most vulnerable, minimizes the number of shots needed and office visits.

Getting all the recommended vaccines at one visit provides the best protection. Studies have shown that spacing out vaccinations over multiple visits causes children more stress and leaves them vulnerable to disease, according to Raheja.

Read this article:
Follow the Right Path: A Traditional Vaccine Schedule - University of Michigan Health System News

Read More...

Nebraska Family Tells of Daughter’s Terrifying Ordeal With ‘Brain on Fire’ Condition – Newsweek

Sunday, January 26th, 2020

A Nebraska couple have spoken of the horrifying ordeal their child went through as a result autoimmune encephalitisa condition sometimes referred to as "brain on fire."

Omaha residents Christina and Brian Beck first noticed that something was wrong with their 14-year-old daughter Meredith in December 2018, KETV reported.

"I mean, it was horrific. We didn't know what was happening," Christina Beck told KETV. '[Meredith] said 'I sometimes feel really scared and confused, and kind of like I'm going really crazy.'"

Suspecting that Meredith was suffering from mental health issues, the Becks took her to see a psychologist, who prescribed the teen anxiety medications. However, these drugs did nothing to alleviate her symptoms and her condition began to worsen.

"She's starting to act lethargic, she started to say she was hearing voices," Christina Beck said. "She would feel like someone was touching her back and no one was there."

The couple said that Meredith began throwing up frequently and also had extreme difficulty getting to sleep.

"We had no idea what was happening and truly, the pediatrician didn't really know and the psychologist didn't know," Christina Beck said.

Then one day the family received a call from Meredith's school saying that she had been found in a catatonic state.

In response, the couple took her to get an electroencephalogram test (EEG), which measures electrical activity in the brain and can reveal whether patients are suffering from seizures.

However, the EEG did not reveal the source of Meredith's problem. With Meredith often relapsing into a catatonic state, the couple subsequently took her to other doctors. However, none could diagnose her condition.

Eventually, one pediatric neurologistDr. Mary Rickardnoticed a tumor the size of a "deflated football" on her left ovary.

"Immediately, when I saw her, I grew very concerned," Rickard told KETV.

She diagnosed her with autoimmune encephalitis, saying that the tumor was causing Meredith's immune system to attack her own brain. Specifically, it led her body to create antibodies that attacked her brain's NMDA receptorsthe same receptors affected by the mind-altering drug PCP.

"Unless you know what you're looking for, it's sometimes difficult," Rickard said. "If it attacks NMDA, that's what the drug PCP works on. So think of a child acting like they're on PCP all day. That's what we're dealing with."

After discovering the tumor, Rickard booked Meredith in for surgery the next day to remove it, while also treating her with steroids and giving her a blood transfusion.

The treatment was successful and after about a month or so, Meredith had made a full recovery.

"The neurologist told us that 12 years ago, our daughter would have been put in a psychiatric unit and she would've died there... because they didn't know as recently as 12 years ago, what was happening or how to stop it," Christina Beck said.

According to the National Institutes of Health, autoimmune encephalitis refers to a group of conditions that occur when the body's own immune system starts to attack healthy brain cells.

This can lead to a range of symptoms, including impaired memory and cognitive abilities, seizures, balance problems, speech problems, vision problems, psychosis, aggression, euphoria, fear, panic attacks, compulsive behaviors, loss of consciousness and coma.

Read this article:
Nebraska Family Tells of Daughter's Terrifying Ordeal With 'Brain on Fire' Condition - Newsweek

Read More...

News Extra precautions being taken in Metro Detroit to prevent the spread of the Coronavirus Jenn – WXYZ

Sunday, January 26th, 2020

DETROIT (WXYZ) Health leaders from around the world are continuing to monitor the spread of the coronavirus, now responsible for the deaths more than 2 dozen people in China.

The outbreak started in the city of Wuhan.

Two cases of the virus have been confirmed in the U.S one north of Seattle and another in Chicago.

Tonight, were learning the CDC is testing 3 people from metro Detroit for the virus.

Infectious disease specialist Dr. Marcus Zervos stresses that unless youve traveled to the affected region in China, or youve been near someone who has, your chances of exposure are very low.

The virus is contagious person-to-person, so its a good idea to wash your hands and the obvious here avoid travel to Wuhan for right now.

Zervos was just in Wuhan in November as part of his job with the Henry Ford Health System.

The city is building a 1,000-bed hospital. Theyre putting up a 1,000-bed hospital in just a period of a week, Zervos says.

Thats the city of Wuhans emergency response to the outbreak of the coronavirus, something Dr. Marcus Zervos with the Henry Ford Health System says presents a lot like the flu. It can also cause fever, cough, and shortness of breath.

For people in Detroit the risk of getting the infection is very rare. It requires travel to China or being exposed to somebody who has been exposed to the virus or has infection with the virus, says Zervos.

The CDC is now testing 3 people from metro Detroit for the highly contagious virus. But Dr. Zervos says Henry Ford, nor Wayne State where he also works, has been made aware of any extra precautions or concerns related to the virus.

Its a new virus, its something we dont have immunity to. And in that way, it can spread possibly pretty easily between people, says Zervos.

In response to the outbreak, U of M has issued a travel warning for china, and restricted travel to the province where the outbreak started.

Michigan State also sent out a memo to students saying that their following CDC and WHO guidelines, but that at this time no programs are affected.

Symptoms of the virus may appear between 2 to 14 days after exposure, and those with weaker immune systems are most at risk,

But Dr. Zervos says for the average metro Detroiter who hasnt been to that region of China, their biggest health risk this time of the year, should be the flu.

Zervos says the way doctors handle possible cases once theyre confirmed, is quarantine.

Right now, there is now vaccine for the virus.

Coronavirus normally starts in animals and then is transmitted to humans.

In this case, it started at a seafood market in Wuhan. And again, its shared person-to-person, so thats why you see so many people in china, especially using public transit, wearing those face masks.

Zervos says thats not a precaution he thinks is necessary here.

Read more here:
News Extra precautions being taken in Metro Detroit to prevent the spread of the Coronavirus Jenn - WXYZ

Read More...

Take care of yourself this winter! – The News on Sunday

Sunday, January 26th, 2020

An unprecedented cold spell has taken over Pakistan and the country, even the safely tropical city of Karachi, has not experienced the kind of chills that it has been suffering this year. In this kind of weather, its understandable that people have chosen to go into hibernation, finding the perfect excuse to stay in bed and not turn up for work. Those who do have to step out of the home have been struggling with warm clothing and temperature control. Fan heaters and inverters have had a lucky run, thanks to the nationwide gas shortage which accompanies harsh winters.

With shorter days and colder weather, amplified by weddings, family reunions and oodles of unhealthy food choices, it tends to get difficult to find the motivation to stay healthy and fit but to counter the general air of overeating and inactivity, there are plenty of wellness tips that may help keep your health on track...

Two-thirds of our body is made of water and therefore, keeping ourselves hydrated is one of the healthiest things to do. Symptoms of dehydration range from headaches to nausea to fatigue but its effects on ones immune system may not always be obvious. If one is hydrated, it keeps mucus membranes moist and, in turn, the immune system functions optimally. The best thing would be to up ones intake of fluids (including of course water), which is incredibly beneficial. Aim to drink at least eight glasses of water a day and see the difference!

Science confirms that poor nutrition impairs the immune response while fresh veggies, fruits, nuts, grains and legumes or pulses are full of immune-boosting properties and antioxidants. It is advisable to eat in season; nature provides fresh, seasonal foods to compensate what our bodies lack at a particular time of the year. For instance, citrus fruits are in season throughout winter and are full of Vitamin C.

Though stress is not always bad, especially when one has a work deadline, studies have linked high stress levels to making a person more susceptible to catching colds and flu. Everyone has a way of coping with and reducing stress; whether its taking a bath, working out, sitting outdoors in the garden or having fun with the kids, do something to unwind. One can also minimize stress by working reasonable hours at their job and using free time to rest and relax alone or with friends and family.

We often overlook the simple things like washing our hands; it is a simple prevention method from germs and diseases. Washing hands regularly with soap for at least 20 seconds, and ensuring they are thoroughly dry, helps control infection. When coughing or sneezing, one should use a tissue and dispose if off. If one becomes mindful of this for a few weeks, it will soon become second nature.

Sleep is essential for ones body to rest, repair and rejuvenate. This is why people look their best after a good nights sleep. The human growth hormone that is released during sleep helps repair ones body at a cellular level besides benefitting the immune system. If one has interrupted or less sleep that the body requires, it significantly reduces the effectiveness of ones immune system; particularly, the natural killer cells which is your bodys first line of defence against germs.

See the article here:
Take care of yourself this winter! - The News on Sunday

Read More...

Oncolytics Biotech: A Small But Very Promising Cancer Player In 2020 – Seeking Alpha

Sunday, January 26th, 2020

Today, we will study why Oncolytics Biotech (ONCY) is risky but attractive in 2020.

Oncolytics Biotech is a clinical-stage company focused on the development of an intravenously delivered immuno-oncolytic virus called Pelareorep. The company is targeting solid tumors and hematological malignancies. Oncolytics Biotech has partnered with multiple big pharma players such as Pfizer (PFE), Merck (MRK), and Roche Holding (OTCQX:RHHBY) to explore the efficacy of Pelareorep in combination with oncology drugs belonging to different classes, across a range of cancer indications.

On December 6, the company received notice from Nasdaq that it was in compliance with the exchanges minimum bid price requirement.

The global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. Unlike surgery, radiotherapy, and chemotherapy, checkpoint inhibitors do not directly target the tumor cells. Instead, they amplify and accelerate the immune system in the patients body to identify and then destroy the tumor cells.

The market opportunity would have been even higher if immunotherapies would not have failed frequently. A major reason for the failure of immunotherapies stems from the ability of tumor cells to alter the microenvironment and avoid getting identified by the bodys immune system. Cancer cells are not foreign bodies like bacteria and viruses. Hence, the immune system finds it difficult to identify them. Besides, immunotherapies also fail when the patient does not have T-cells. T-cells also require to be at the location of the tumor. There are certain indications where only around 20% of patients are currently benefitting from checkpoint inhibitors.

The immune system is categorized into two types, innate and adaptive. The innate immune system comprises of nonspecific defense mechanisms such as skin, chemicals in the blood, and natural killer cells. This activates immediately or within hours of an antigen's appearance in the body. The adaptive immune system comprises of T-cells, which generate an antigen-specific immune response. Adaptive immunity also involves memory, thereby resulting in improved response to that specific antigen in the future.

To make immunotherapies work, there are three core requirements. T-cells have to be present in the body. These T-cells have to be moved to the location of the tumor. The tumor cells also need to express PD-L1, the target of checkpoint inhibitors. Hence, to make checkpoint inhibitors work, we need to increase the number of T-cells, move them to the location of the tumor, and cause the tumor to overexpress PD-L1.

Oncolytics Biotech is working on Pelareorep, an oncolytic virus that aims to activate the innate and adaptive immune system in the patients bodies. This, in turn, is expected to increase inflammation in tumors, which would cause overexpression of checkpoint inhibitors. This will finally help the immunotherapy to effectively detect the tumor cell.

Oncolytic viruses are retroviruses that replicate only and specifically in tumor cells. Hence, there is no effect on normal tissues. Hence, the goal of oncolytic viruses is to infect and replicate into tumor cells and allow the immune system to identify these tumors.

Pelareoreps genome is double-stranded RNA. The immune system can detect this structure very easily in normal cells. Cancer tissue does not have the ability to identify the double-stranded RNA, thereby allowing the virus to replicate. The companys first patents were based on this understanding of biology.

Pelareorep not only activates the innate immune system to destroy tumor cells but also activates the adaptive immune system. When tumor cells are destroyed by the innate immune systems natural killer cells, it leads to cell debris. Thereafter, the adaptive immune system or T-cells learn to identify the tumor cells based on this debris.

Pelareorep is currently being evaluated in combination with other cancer therapies in metastatic breast cancer, pancreatic cancer, and relapsed/refractory multiple myeloma indications.

Oncolytic Biotech is also developing a biomarker blood test to identify patients most likely to benefit from Pelareorep. In April 2017, the company had reported median OS (overall survival) of 20.9 months in Phase 2 randomized, open-label study in patients with mutated p53 metastatic breast cancer when treated with Pelareorep combined with paclitaxel. This was more than double the OS of 10.4 months seen for patients treated only with paclitaxel. Since the OS benefit is a function of the immune system, the FDA has asked the company to measure the strength of the immune system.

Oncolytic Biotech is using TCR sequencing to evaluate the robustness and reactivity of the patients immune system called T-cell clonality. The biomarker blood test can help evaluate the patients immune reserve and thereby predict the response to this oncolytic virus therapy. Within three weeks, the company can evaluate whether new T-cells are being formed and if the patient is actually responding to therapy.

Oncolytic Biotech has reported the creation of new T-cells and existing T-cells becoming reactive to the tumor for the first early-stage breast cancer patient treated with Pelareorep combined with Roches Holdings Tecentriq in AWARE-1 trial. Unlike normal individuals in an urban setting whose forms 2-3 new T-cell clones every month, the patient had about 450 T-cells. This is a clinical proof of Pelareoreps ability to train the immune system.

The company also demonstrated an increase in T-cells within the tumor as well as at tumor periphery. The company expects to complete enrollment of this study as well as announce interim data in the first quarter of 2020. Oncolytics Biotech also expects final data from this trial in mid-2020.

Oncolytics Biotech, Pfizer, Merck KGaA, and a leading cancer research network, PrECOG, are also studying a combination of Pelareorep, Bavencio, and paclitaxel in three-arm open-label Phase 2 study, BRACELET-1 in metastatic breast cancer indication. The company plans to commence enrollment in this trial in the first quarter and complete enrollment by the fourth quarter of 2020. The company also expects interim data from this trial in the fourth quarter of 2020 and the final data in the first half of 2021.

In May 2018, Oncolytics Biotech received SPA (special protocol assessment) from the FDA for its Pelareorep program in breast cancer indication. FDA recommended the company to identify a biomarker for this therapy before the Phase 3 trial. The agency has also confirmed that only one successful Phase 3 trial will be required for securing approval for this therapy.

In October 2019, the company presented clinical data across 13 clinical studies across various cancer indications, which demonstrated the effectiveness of intravenous delivery for Pelareorep. 81% of the tumors were positive for replicating the virus. Excluding melanoma skin biopsies, the number of tumors with replicating virus was almost 96%.

Pelareorep has demonstrated efficacy in combination with CDK 4/6 inhibitors in early-stage breast cancer indication in pre-clinical studies. The drug is also demonstrating activity in combination with proteasome inhibitor, Amgens (AMGN) Kyprolis (carfilzomib) in an ongoing NCI's sponsored multiple myeloma study. In December 2019, the company announced positive results for a combination of Pelareorep and carfilzomib in multiple myeloma.

Oncolytics Biotech expects interim data from both the above trials in the fourth quarter of 2020.

In November 2019, Oncolytics Biotech announced a partial response of 17.4 months from 1b REO 024 study evaluating Pelareorep in combination with Mercks (MRK) Keytruda in Advanced Pancreatic Adenocarcinoma patients. The partial response has already exceeded the historical overall survival data in this indication. The company is now evaluating this combination regimen in the Phase 2 trial. Oncolytics Biotech expects to complete Phase 2 enrolment by mid-2020 and release final data from the trial in the second half of 2020.

Pelareorep has demonstrated favorable safety and tolerability in these trials.

Oncolytics Biotech has a strong patent estate for Pelareorep, which involves 399 patents worldwide. The composition of matter patent protects the particular strain used in this therapy. This IP estate will protect the therapy from competition till 2028.

Pelareorep scores ahead of other OV (oncolytic virus) therapies in three key aspects of delivery, safety, and efficacy. Unlike other OVs which require intratumoral delivery, Pelareorep is administered intravenously. This will allow nurses to administer Pelareorep with chemotherapy drugs the same way they infuse other cancer therapies. Intratumoral delivery requires specialized training and hence is costlier for the oncologist.

Pelareorep has also been found to target cancer cells across the body, while not affecting normal cells. This systemic mechanism of action is yet to be demonstrated by other OVs. Finally, Oncolytic Biotechs efforts to identify a biomarker for this therapy can help identify patients most likely to benefit from Pelareorep.

Oncolytic Biotechs growth prospects depend solely on the clinical and commercial prospects of its investigational IOV (immuno-oncolytic virus), Pelareorep. This exposes the company to a high degree of business concentration risk. The companys research programs are in Phase 1 or Phase 2 of clinical development.

The probability of final regulatory approval for an asset currently in Phase 1 in oncology indication is only 5.1%. The probability of final regulatory approval for an asset currently in Phase 2 in oncology indication is only 8.1%. Based on these numbers, we see that the company is exposed to a high degree of R&D failure risk.

Oncolytic Biotech has cash of $9.28 million and zero debt on its balance sheet. In the last 12 months ending September 2019, the company spent around $12.9 million cash on operational activities. While the company is scheduled to earn up to 86.6 million from collaborators, these payments are spread over multiple years. Hence, the chances of a possible dilutive round of funding remain high. The company may also raise some debt to fund its operations.

Finally, the company is not yet profitable and may continue to be loss-making for many more years. This can dampen the companys valuations.

On January 2, Roth Capital analyst, Jonathan Aschoff reiterated the Buy rating and increased Oncolytics target price from $6.80 to $9.0. The analyst expects final data from the Phase 2 AWARE-1 breast cancer trial in the second quarter of 2020. In December 2019, Echelon Wealth Partners Douglas Loe reiterated buy rating for the stock and set target price at $8.43. In May 2019, RBC Capital analyst Douglas Miehm maintained an Outperform rating and set target price at $6.89.

The above table highlights the change in analyst recommendations and target price for the stock since December 2018.

Oncolytics Biotech will not have a steady stream of revenues for the foreseeable future. Analysts expect the company to reduce its loss per share in 2020. However, the improvement will most likely be due to additional equity dilution and not a reduction in net losses.

Oncolytic Biotech stands a solid chance of being an acquisition target for big pharma companies. There have already been many licensing and acquisition transactions in the oncolytic virus space.

In this backdrop, I believe the target price of $6.0 is a likely estimate of the company's share price after 12 months. Although a very risky stock, the companys oncolytic virus technology holds huge promise in the oncology space. Hence, I recommend investors with above-average risk appetite to consider this stock in 2020.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Visit link:
Oncolytics Biotech: A Small But Very Promising Cancer Player In 2020 - Seeking Alpha

Read More...

Study shows high amount of forever chemicals in tap water; local systems respond – WTOP

Sunday, January 26th, 2020

A new study by an environmental watchdog group finds more drinking water systems containing "forever chemicals," including in the D.C. region.

A new report by an environmental watchdog group finds more drinking water systems around the country than previously believed are contaminated by what the group characterizes as high levels of forever chemicals, which arent broken-down over time.

Water systems in D.C. and Prince Georges County, Maryland, were among those with a high amount of the man-made chemicals, known as perfluoroalkyl substances, or PFAS, according to the Environmental Working Group study.

Of tap water samples from 44 places in 31 states and D.C., only one location had no detectable PFAS, according to the EWG study.

In D.C., the groups testing found 21.7 parts per trillion, while in Prince Georges County, the values were 17.8 parts per trillion.

The advocacy group cites 1 part per trillion of PFAS as a safety threshold.

The Environmental Protection Agency has not set any nationwide limits. However, in a 2016 water health advisory, the EPA recommended a level of no more than 70 parts per trillion, which the agency said offers a margin of protection for all Americans throughout their life from adverse health effects resulting from exposure.

In December, the EPA said it would move forward to study two chemicals that fall under the PFAS umbrella perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFAS) to determine whether it should set a maximum level for those chemicals. The EPA has known about the existence of PFAS in drinking water for almost two decades.

The chemicals, which are used to make carpets, clothing, paper packaging for food, cookware and firefighting materials, have been in use since the 1940s. Exposure to the chemicals over certain limits has been linked to excessive cholesterol levels, ulcerative colitis, thyroid disease, testicular and kidney cancer, and problems in pregnancies, according to the EPA.

John Lisle, of DC Water, acknowledges the utility and scientists are continuing to learn about PFAS chemicals.

Testing in 2014 by DC Water and other local utilities did not detect the chemicals, but the detection threshold was higher, Lisle said. Newer, more precise methods of testing have since been developed to detect very low levels of PFAS.

Still, Lisle said risk to humans is low: The report confirms the PFAS detected in tests conducted in D.C. are at levels well below any established EPA health advisory for these compounds.

The Centers for Disease Control and Prevention, on its website, said the safety risk from PFAS is still unclear: Human health effects from exposure to low environmental levels of PFAS are uncertain. Studies of laboratory animals given large amounts of PFAS have found that some PFAS may affect growth and development, reproduction, thyroid function, the immune system and injure the liver.

Though the environmental advocacy group would like to reduce the amount of PFAS in the nations water, inexpensive home carbon filters, as well as reverse osmosis, and ion exchange water treatment systems appear to be helpful in minimizing risk.

Lyn Riggins, with WSSC Water, which provides tap water in Prince Georges County, said: For more than 101 years, our water has consistently met all Safe Drinking Water Act requirements. In fact, we have never had a single drinking water quality violation in our history.

The [EPA] does not yet regulate PFAS compounds, but maintains a health advisory of 70 parts per trillion for two of the most common compounds, PFOA and PFOS, said Riggins. The EWG analysis reported WSSC Waters total PFAS to be 17.8 ppt, well below the EPAs health advisory.

The Associated Press contributed to this report.

Like WTOP on Facebook and follow @WTOP on Twitter to engage in conversation about this article and others.

2020 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

Read this article:
Study shows high amount of forever chemicals in tap water; local systems respond - WTOP

Read More...

Something Chronic: How a Gut Infection May Lead to IBS – Technology Networks

Monday, January 13th, 2020

Sometimes the end of an intestinal infection is just the beginning of more misery. Of those who contract travelers diarrhea, for example, an unlucky few go on to develop irritable bowel syndrome (IBS), a chronic inflammation of the intestinal tract.

Scientists arent sure exactly how this happens, but some think an infection may contribute to IBS by damaging the gut nervous system. A new Rockefeller study takes a close look at why neurons in the gut die and how the immune system normally protects them.

Conducted with mice, the experiments offer insight on IBS and could point toward potential new treatment approaches.

Keeping inflammation in check

In a healthy gut, the immune system must strike a careful balance between responding to threats and keeping that response in check to avoid damage.

Inflammation helps the gut ward off an infection, but too much of it can cause lasting harm, says Daniel Mucida, an associate professor and head of the Laboratory of Mucosal Immunology. Our work explores the complex mechanisms that prevent inflammatory responses from destroying neurons.

To understand the effects of an infection on the nervous system, Mucida and his colleagues gave mice a weakened form of Salmonella, a bacterium that causes food poisoning, and analyzed neurons within the intestine. They found that infection-induced a long-lasting reduction of neurons, an effect they attributed to the fact these cells express two genes, Nlrp6 and Caspase 11, which can contribute to a specific type of inflammatory response.

This response, in turn, can ultimately prompt the cells to undergo a form of programmed cell death. When the researchers manipulated mice to eliminate these genes specifically in neurons, they saw a decrease in the number of neurons expiring.

This mechanism of cell death has been documented in other types of cells, but never before in neurons, says Fanny Matheis, a graduate student in the lab. We believe these gut neurons may be the only ones to die this way.

Macrophages to the rescue

Its not yet clear exactly how inflammation causes neurons to commit cell suicide, yet the scientists already have clues suggesting it might be possible to interfere with the process. The key may be a specialized set of gut immune cells, known as muscularis macrophages.

Previous work in Mucidas lab has shown that these cells express inflammation-fighting genes and collaborate with the neurons to keep food moving through the digestive tract. If these neurons die off, as happens in an infection, a possible result is constipationone of a number of unpleasant IBS symptoms. In their recent report, the team demonstrate how macrophages come to the neurons aid during an infection, ameliorating this aspect of the disorder.

Their experiments revealed that macrophages possess a certain type of receptor molecule that receives stress signals released by another set of neurons in response to an infection. Once activated, this receptor prompts the macrophage to produce molecules called polyamines, which the scientists think might interfere with the cell death process.

Getting back to normal

In other experiments, the researchers found that Salmonella infection alters the community of microbes within the guts of miceand when they restored the animals intestinal flora back to normal, the neurons recovered.

Using what we learned about the macrophages, one could think about ways to disrupt the inflammatory process that kills the neurons, says Paul Muller, a postdoctoral fellow in the lab.

For instance, it might be possible to develop better treatments for IBS that work by boosting polyamine production, perhaps through diet, or by restoring gut microbial communities. Since short-term stress responses also appear to have a protective effect, Muller thinks it may also be helpful to target that system.

Reference

Matheis et al. (2020) Adrenergic Signaling in Muscularis Macrophages Limits Infection-Induced Neuronal Loss. Cell. DOI: https://doi.org/10.1016/j.cell.2019.12.002

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Here is the original post:
Something Chronic: How a Gut Infection May Lead to IBS - Technology Networks

Read More...

White blood cells: Function, ranges, types, and more – Medical News Today

Monday, January 13th, 2020

White blood cells circulate around the blood and help the immune system fight off infections.

Stem cells in the bone marrow are responsible for producing white blood cells. The bone marrow then stores an estimated 8090% of white blood cells.

When an infection or inflammatory condition occurs, the body releases white blood cells to help fight the infection.

In this article, learn more about white blood cells, including the types and their functions.

Health professionals have identified three main categories of white blood cell: granulocytes, lymphocytes, and monocytes. The sections below discuss these in more detail.

Granulocytes are white blood cells that have small granules containing proteins. There are three types of granulocyte cells:

These white blood cells include the following:

Monocytes are white blood cells that make up around 28% of the total white blood cell count in the body. These are present when the body fights off chronic infections.

They target and destroy cells that cause infections.

According to an article in American Family Physician, the normal range (per cubic millimeter) of white blood cells based on age are:

The normal range for a pregnant women in the 3rd trimester is 5,80013,200 per cubic millimeter.

If a person's body is producing more white blood cells than it should be, doctors call this leukocytosis.

A high white blood cell count may indicate the following medical conditions:

Surgical procedures that cause cells to die can also cause a high white blood cell count.

If a person's body is producing fewer white blood cells than it should be, doctors call this leukopenia.

Conditions that can cause leukopenia include:

Doctors may continually monitor white blood cells to determine if the body is mounting an immune response to an infection.

During a physical examination, a doctor may perform a white blood cell count (WBC) using a blood test. They may order a WBC to test for, or rule out, other conditions that may affect white blood cells.

Although a blood sample is the most common approach to testing for white blood cells, a doctor can also test other body fluids, such as cerebrospinal fluid, for the presence of white blood cells.

A doctor may order a WBC to:

The following are conditions that may impact how many white blood cells a person has in their body.

This is a condition wherein a person's body destroys stem cells in the bone marrow.

Stem cells are responsible for creating new white blood cells, red blood cells, and platelets.

This is an autoimmune condition wherein the body's immune system destroys healthy cells, including red and white blood cells.

HIV can decrease the amount of white blood cells called CD4 T cells. When a person's T cell count drops below 200, a doctor might diagnose AIDS.

Leukemia is a type of cancer that affects the blood and bone marrow. Leukemia occurs when white blood cells rapidly produce and are not able to fight infections.

This condition causes a person's body to overproduce some types of blood cells. It causes scarring in a person's bone marrow.

Whether or not a person needs to alter their white blood cell count will depend on the diagnosis.

If they have a medical condition that affects the number of white blood cells in their body, they should talk to a doctor about the goals for their white blood cell count, depending on their current treatment plan.

A person can lower their white blood cell count by taking medications such as hydroxyurea or undergoing leukapheresis, which is a procedure that uses a machine to filter the blood.

If a person's white blood cell count is low due to cancer treatments such as chemotherapy, a doctor may recommend avoiding foods that contain bacteria. This may help prevent infections.

A person can also take colony-stimulating factors. These may help prevent infection and increase the number of white blood cells in the body.

White blood cells are an important part of the body's immune system response. There are different types of white blood cell, and each has a specific function in the body.

Certain conditions can affect the number of white blood cells in the body, causing them to be too high or too low.

If necessary, a person can take medication to alter their white blood cell count.

More here:
White blood cells: Function, ranges, types, and more - Medical News Today

Read More...

The Secrets to a Healthier, Happier You in 2020 Podcast Episode 3 Reveals Secrets to Maintaining a Healthy Immune System – Us Weekly

Monday, January 13th, 2020

Staying healthy in 2020! The No. 1 factor in remaining healthy and not getting sick is a strong immune system!

On episode 3 of The Secrets to a Healthier, Happier You in 2020 podcast, Us Weeklys Christina Garibaldi is joined by RxSavers medical expert Dr. Holly Phillips to discuss everything you need to know about maintaining a healthy immune system.

Its essentially our bodies defense against everything outside, and particularly diseases and infections, Phillips explains. Ranging from viruses and bacteria and everything thats outside of our body that we want to keep out.

The first tip? Get enough sleep.

I really have to emphasize that, the doc reveals. If you dont get enough sleep, it creates a cascade of stress hormones.

During the episode, Phillips also reveals the right and wrong foods to help your immune system stay strong.

If youd like to boost your immune system, make your plate as colorful as possible, she says. Brightly colored fruits and vegetables If its really bright, you know you have the antioxidants you need.

For more tips to avoid catching the common cold or ending up stuck on the couch for weeks, listen to Secrets to a Healthier, Happier You episode 3.

The podcast, which also tackles mental health, New Years resolutions and more, is available on Apple Podcasts, Spotify, Google Podcasts and Stitcher.

Read the original here:
The Secrets to a Healthier, Happier You in 2020 Podcast Episode 3 Reveals Secrets to Maintaining a Healthy Immune System - Us Weekly

Read More...

Are consumers concerned about their immunity? – New Food

Monday, January 13th, 2020

Based on FMCG Gurus The Impact of Immunity Global Report 2020, Will Cowling explores how the results reflect a consumer shift towards a focus on immunity when considering diet.

Immunity is becoming a key area in which consumers are looking to actively improve. This is due to many factors including changing dietary habits and greater levels of inactivity, which is having an impact on consumer health. Many people can be concerned about germs and bacteria and are also becoming more educated on the topic of immunity. This is leading to consumers being more proactive when it comes to addressing the immune system. So, what are consumers doing to improve their immune system?

FMCG Gurus research shows that 54 percent of global consumers believe to have a good or very good immune system. However, 25 percent still believe they do not have a good immune system. The growing rise of consumers understanding the importance of immunity aligns with consumers embracing the concepts of holistic health and being healthier for longer. People are recognising the link between their immune system and their overall health. This being said, three in 10 consumers state they have suffered from health problems which has impacted the quality of their day-to-day life.

The growing rise of consumers understanding the importance of immunity aligns with consumers embracing the concepts of holistic health and being healthier for longer

Consumers associate many different variables to what constitutes a poor immune system. Globally, the majority of people believe that being easily susceptible to day-to-day illness such as catching a cold (61 percent) is a key sign to a poor immune system. FMCG Gurus consumer insights show that four in 10 consumers feel vulnerable to illness. This is a further reflection of how a considerable proportion of consumers across the globe are not satisfied with their immune system.

Half of consumers in the last 12 months have looked to improve their immune systems. Consumers are taking a proactive approach to health maintenance and recognise that a good immune system is not linked to physical health alone. Mental wellness is also at the forefront of consumers minds as 54 percent stated that they have looked to improve their mental wellness to improve their overall quality of life and immune system.

Consumers are taking a proactive approach to health maintenance and recognise that a good immune system is not linked to physical health alone

One key movement that consumers are trying to improve their immune system through is by eating more fresh vegetables (63 percent). Globally, consumers are changing their diets, another key change which have consumers have made is increase their protein intake (62 percent). This shows that consumers are taking an active approach to their health. This is also seen as 35 percent of consumers stated that they do not suffer with any problems but wanted to take a proactive approach to their health.

Food and beverage products are one of the main ways in which consumers look to improve their health. Globally, 58 percent of consumers would be interested in products that promote heart health, cognitive health and immune health benefits. This is the same with nutritional supplements; although the research shows consumers may not necessarily be seeking such products out, it does show that they want products with active ingredients. FMCG Gurus research shows that iron is the ingredient consumers most associate with boosting their immune systems (70 percent).

Consumers are now prioritising their health and are actively looking to keep their immune system in top condition to stay fitter and healthier for longer. The rise in people taking a proactive approach has led to many opportunities within food and drink. As such, the industry should encourage consumers to take steps to improve their health and wellness in general, because this will have a positive impact on their immunity.

As Marketing Manager of FMCG Gurus, Will Cowling is responsible for managing day to day marketing tasks ranging from campaigns to PR, to managing content on social channels and the website. Understanding the business and the industry is key to providing innovative ideas and producing quality content. He has a strong focus on evaluating consumer perceptions and deciphering insights.

See the rest here:
Are consumers concerned about their immunity? - New Food

Read More...

New Podcast Reveals Tips to Boost Your Immune System – In Touch Weekly

Monday, January 13th, 2020

All available episodes can be streamed on all major podcast platforms: LISTEN NOW

Staying healthy in 2020! The No. 1 factor in remaining healthy and not getting sick is a strong immune system!

On episode 3 of The Secrets to a Healthier, Happier You in 2020 podcast, Us Weeklys Christina Garibaldi is joined by RxSavers medical expert Dr. Holly Phillips to discuss everything you need to know about maintaining a healthy immune system.

Its essentially our bodies defense against everything outside, and particularly diseases and infections, Phillips explains. Ranging from viruses and bacteria and everything thats outside of our body that we want to keep out.

The first tip? Get enough sleep.

I really have to emphasize that, the doc reveals. If you dont get enough sleep, it creates a cascade of stress hormones.

During the episode, Phillips also reveals the right and wrong foods to help your immune system stay strong.

If youd like to boost your immune system, make your plate as colorful as possible, she says. Brightly colored fruits and vegetables If its really bright, you know you have the antioxidants you need.

For more tips to avoid catching the common cold or ending up stuck on the couch for weeks, listen to Secrets to a Healthier, Happier You episode 3.

The podcast, which also tackles mental health, New Years resolutions and more, is available on Apple Podcasts, Spotify, Google Podcasts and Stitcher.

Continued here:
New Podcast Reveals Tips to Boost Your Immune System - In Touch Weekly

Read More...

Seeking immunity from the ill effects of obesity – The Irish Times

Monday, January 13th, 2020

Your research looks at the links between obesity and the immune system and metabolism in children. Why?

We know that obesity in adults is linked with more than 200 different diseases. Research tells us that in obesity the immune system becomes overactivated, which damages tissues in the body, and some immune cells become depleted so they cant protect properly. I want to see how we can protect children living with obesity from these immune system changes, to protect them against future disease and damage.

How did you get into this area of research?

I am the first person in my family to go to university. I went to Maynooth University through the access programme, then after my PhD I worked as a Newman scholar with Donal OShea and Lydia Lynch in University College Dublin.

We were interested in a type of cell in the immune system called the invariant natural killer T-cell. It attacks viruses and tumours, but stops working properly in obesity. When I moved back to Maynooth to set up my own research group, I thought it would be interesting to look at immune changes in younger people living with obesity.

What did you find when you looked at children with obesity?

We did a project with the National Childrens Research Centre, where we worked with children living with obesity at age six, 10 and 16. We could see kids as young as six were starting to show signs of chronic inflammation, a type of immune-system overactivation.

They already had molecular markers of it in their bloodstream. I thought maybe if we can intervene with children who are living with obesity and stop this immune activation, turn down the chronic inflammation, we could perhaps delay or reduce related disease in adulthood.

We are looking at options there, using a gut hormone that is known to tone down chronic inflammation. There is a shorter-term outlook too: in another project we are looking at obesity and vaccinations.

Tell us more about that.

We know that some vaccines are less effective in adults with obesity, which makes sense. After all, we have been showing for 15 years that in obesity the immune system is overactivated or exhausted.

So we looked at the responses to childhood measles and rubella vaccinations, and in a small study we found that children with obesity have far less of the antibody titre after vaccinations, which means they may not be as well protected from these diseases. Now we are looking at this more closely in larger numbers of children, and we hope to examine responses to the HPV vaccine too.

What do you love about your work?

I just really enjoy it. Of course there are times when things dont work out as you expect, but Im a sunny-side-up kind of person, and you just rethink the experiment or find a new direction.

What do you do to take a break?

I find that exercise is a great way to clear the mind. When I was a teenager I did a lot of kickboxing, I was number one in the world at one point. In the last few years I have been doing CrossFit, and I was involved in opening a gym where I teach classes. Its one of those things that, no matter how you feel at the start of the class, you will always be happy about having done it afterwards. Its a great way to unwind.

Read more from the original source:
Seeking immunity from the ill effects of obesity - The Irish Times

Read More...

How immersing yourself in nature benefits your health – PBS NewsHour

Monday, January 13th, 2020

How long does it take to get a dose of nature high enough to make people say they feel healthy and have a strong sense of well-being?

Precisely 120 minutes.

In a study of 20,000 people, a team led by Mathew White of the European Centre for Environment & Human Health at the University of Exeter, found that people who spent two hours a week in green spaces local parks or other natural environments, either all at once or spaced over several visits were substantially more likely to report good health and psychological well-being than those who dont. Two hours was a hard boundary: The study, published last June, showed there were no benefits for people who didnt meet that threshold.

The effects were robust, cutting across different occupations, ethnic groups, people from rich and poor areas, and people with chronic illnesses and disabilities.

Its well-known that getting outdoors in nature can be good for peoples health and well-being, but until now weve not been able to say how much is enough, White said. Two hours a week is hopefully a realistic target for many people, especially given that it can be spread over an entire week to get the benefit.

The study by White and his colleagues is only the latest in a rapidly expanding area of research that finds nature has robust effects on peoples health physically, mentally, and emotionally.

When I wrote Last Child in the Woods in 2005, this wasnt a hot topic, said Richard Louv, a journalist in San Diego whose book is largely credited with triggering this movement and who coined the term Nature Deficit Disorder. This subject was virtually ignored by the academic world. I could find 60 studies that were good studies. Now its approaching and about to pass 1,000 studies, and they point in one direction: Nature is not only nice to have, but its a have-to-have for physical health and cognitive functioning.

These studies have shown that time in nature as long as people feel safe is an antidote for stress: It can lower blood pressure and stress hormone levels, reduce nervous system arousal, enhance immune system function, increase self-esteem, reduce anxiety, and improve mood. Attention Deficit Disorder and aggression lessen in natural environments, which also help speed the rate of healing. In a recent study, psychiatric unit researchers found that being in nature reduced feelings of isolation, promoted calm, and lifted mood among patients.

The growing body of research combined with an intuitive understanding that nature is vital and increased concerns about the exploding use of smart phones and other forms of technology has led to tipping point at which health experts, researchers, and government officials are now proposing widespread changes aimed at bringing nature into peoples everyday lives.

WATCH: Why doctors are increasingly prescribing nature

For example, researchers and policymakers now talk about park deserts in urban areas. Cities are adding or enhancing parks, and schools and other institutions are being designed with large windows and access to trees and green space or blue space, as in aquatic environments. Businesses are increasingly aware of the desire among employees for access to green spaces. Its needed to attract a skilled work force, said Florence Williams, author of The Nature Fix. Young people are demanding high-quality outdoor experiences.

The number of forest schools which have long been a tradition in Scandinavia and where much of the learning takes place in natural settings in the outdoors has mushroomed in the United States, up by 500 percent since 2012, according to Louv. Oregon recently passed a ballot measure to raise money for outdoor schools, and the state of Washington just became the first state to license outdoor preschools, where much of the play and learning occurs outside.

The organization Children & Nature Network, founded by Louv and others, advocates for more time in nature for children, tracks the research, and has a long list of abstracts that summarize studies on the subject on its website.

And The Trust for Public Lands (TPL) has just finished a seven-year project to map the parks of the U.S., with the aim of identifying places in need of parkland. Weve mapped 14,000 communities, 86 percent of the nation, and looked at who does and doesnt live within a 10-minute walk of a park, said Adrian Benepe, a senior vice president of TPL. The organization has a Ten Minute Walk campaign to work with mayors across the U.S. to make sure all people have that kind of access.

An increasing number of healthcare providers are also embracing the back-to-nature paradigm. One organization, Park RX America, founded by Robert Zarr of Unity Healthcare in Washington, D.C., declares its mission to decrease the burden of chronic disease, increase health and happiness, and foster environmental stewardship, by virtue of prescribing Nature during the routine delivery of healthcare by a diverse group of health care professionals. The organization has 10,000 parks in its prescribing platform.

The global Association of Nature and Forest Therapy Guides shows clients how to use immersion in nature for healing. The forest is the therapist, the groups slogan reads. The guides open the door.

Studies show that the effects of nature may go deeper than providing a sense of well-being, helping to reduce crime and aggression. A 2015 study of 2,000 people in the United Kingdom found that more exposure to nature translated into more community cohesion and substantially lower crime rates.

And while more vegetation is thought to encourage crime by providing security for criminals, another study found the opposite vegetation abundance is associated with a reduction in assault, robbery, and burglary, although not theft.

Still, many of these studies are correlational rather than causal. That means its hard to show that natural landscapes cause these effects, though these things happen when people are in a natural environment.

Sara Weber, professor of family medicine at the University of Michigan, noted that there are no randomized, controlled studies on the effects of nature on human health. Nonetheless, she said, there are epidemiological studies and measurements of before and after exposure to nature, and the results from this research are robust.

Peter H. Kahn, a professor of psychology at the University of Washington who has worked on these issues for decades, is encouraged by the new focus on the subject but concerned that the growing interest in more contact with nature relies too much on only experiencing it visually. Thats important, but an impoverished view of what it means to interact with the natural world, he said. We need to deepen the forms of interaction with nature and make it more immersive.

What are the active ingredients in a dose of nature? Pioneers in this work, Rachel and Stephen Kaplan, who began studying the subject in the 1970s, devised Attention Restoration Theory, which holds that paying attention in bustling cities, at work, or in other stressful environments requires a good deal of effortful attention. In a natural environment, however, the Kaplans found that people paid attention more broadly and in a less effortful way, which leads to far more relaxed body and mind.

Japanese researchers have studied forest bathing a poetic name for walking in the woods. They suspect aerosols from the forests, inhaled during a walk, are behind elevated levels of Natural Killer or NK cells in the immune system, which fight tumors and infections. A subsequent study, in which essential oils from cedars were emitted in a hotel room where people slept, also caused a significant spike in NK cells.

However this growing field might be defined, it is gaining momentum. In a recent paper, 26 authors laid out a framework to create a formal role for the positive impacts nature has on mental health and to formulate a model for conserving nature in cities and integrating it into planning for these health effects.

However this growing field might be defined, it is gaining momentum. In a recent paper, 26 authors laid out a framework to create a formal role for the positive impacts nature has on mental health and to formulate a model for conserving nature in cities and integrating it into planning for these health effects.

We have entered the urban century, with two-thirds of humanity projected to be living in cities by 2050, said Gretchen Daily, director of the Natural Capital Project at Stanford University and a senior author of a recent paper arguing that the cognitive and emotional benefits of nature should be factored into economic ecosystem service models. There is an awakening underway today to many of the values of nature and the risks and costs of its loss. This new work can help inform investments in livability and sustainability of the worlds cities.

While the research has grown leaps and bounds, Kahn and others argue in a recent review paper that research into the topic is still lacking in many ways, and they lay out a research agenda they say would help formalize the role of nature in public health policy.

Understanding natures therapeutic effects may be arriving at a propitious moment. Some studies have found that anxiety over climate change is a growing phenomenon. Ironically, one of the best antidotes for that might be a dose of green space.

If I am feeling depressed and anxious and worried about the environment, Weber said, then one of the best things I can do is go out in nature.

This article is reproduced with permission from Yale Environment 360. It was first published on January 9, 2020. Find the original story here.

Follow this link:
How immersing yourself in nature benefits your health - PBS NewsHour

Read More...

Adaptive and Genentech Partner to Use clonoSEQ Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic…

Monday, January 13th, 2020

SEATTLE, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global diagnostic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) to utilize Adaptives next-generation sequencing (NGS)-based clonoSEQAssay to assess minimal residual disease (MRD) status in response to venetoclax in the registrational Phase III CRISTALLO (CO41685) study for the treatment of newly diagnosed people with chronic lymphocytic leukemia (CLL) plus additional future venetoclax studies in CLL. Adaptive and Genentech will partner to incorporate the clonoSEQ Assay to measure MRD status as a primary endpoint in this registrational study. Under the terms of the agreement, Adaptive will receive upfront and sample testing payments to advance the development and potential expedited approval of venetoclax in this setting.

Adaptive is pleased to partner with Genentech to support the continued clinical development and potential regulatory approval of venetoclax in people with untreated CLL, which expands our work with Genentech in oncology, said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. This partnership represents another significant step towards the adoption of MRD status as a primary clinical endpoint using clonoSEQ as the preferred MRD test. This is Adaptives second meaningful partnership which we recently announced that includes the use of clonoSEQ in the development of venetoclax.

Venetoclax is a first-in class small molecule selective B-cell lymphoma-2 (BCL-2) inhibitor being studied in investigational trials for the treatment of people with previously untreated CLL or small lymphocytic lymphoma (SLL). Adaptive and Genentech will evaluate the depth and duration of response to venetoclax and obinutuzumab by using Adaptives clonoSEQ Assay as a primary endpoint to measure and monitor MRD negativity from peripheral blood in newly diagnosed CLL. clonoSEQ is the only MRD test authorized by the U.S. Food and Drug Administration (FDA) to detect and monitor MRD in multiple myeloma (MM) and B-Cell acute lymphoblastic leukemia (ALL) using DNA from bone marrow samples.clonoSEQ is available as a laboratory develop test (LDT) in CLL using DNA from peripheral blood and bone marrow.

MRD is a measure of the amount of cancer in the body, specifically the very small number of cancer cells that remain during or after treatment. MRD testing can be useful to see if a patient is responding to treatment or if the cancer has come back

About the clonoSEQAssay

The clonoSEQ Assay was granted de novo designation and marketing authorization by FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) using DNA from bone marrow samples. clonoSEQ is the first and only FDA-authorized in vitro diagnostic assay for MRD testing. It is also the first clinical diagnostic powered by immunosequencing to receive FDA clearance. clonoSEQ leverages Adaptives proprietary immunosequencing platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment. The assay provides standardized, accurate and sensitive measurement of MRD that allows physicians to predict patient outcomes, assess response to therapy over time, monitor patients during remission and detect potential relapse. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes are strongly associated with MRD levels measured by the clonoSEQ Assay in patients diagnosed with ALL and MM. More than 175 million people in the US now have access to clonoSEQ through Medicare and private payor coverage.

clonoSEQ is a single-site assay performed at Adaptive Biotechnologies. It is also available as a CLIA-regulated laboratory developed test (LDT) service for use in other lymphoid cancers. For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visitwww.clonoSEQ.com/technical-summary.

About Adaptive Biotechnologies

Adaptive Biotechnologiesis a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is natures most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com.

Forward Looking Statements

This press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding Adaptive Biotechnologies partnership with Genentech, ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words may, will, expect, plan, believe, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents the Company files with the Securities and Exchange Commission (the "SEC") from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

ADAPTIVE MEDIABeth Keshishian917-912-7195media@adaptivebiotech.com

ADAPTIVE INVESTORSLynn LewisorCarrie Mendivil415-937-5405investors@adaptivebiotech.com

The rest is here:
Adaptive and Genentech Partner to Use clonoSEQ Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic...

Read More...

Frighten Them and They Will Believe It – Psychology Today

Monday, January 13th, 2020

False information spreads faster than the truth on the internet, and false information about scientific topics is among the most rapidly spread categories. What makes us prone to believing something that is utterly or even mostly incorrect? Can anything be done to counteract our acceptance of incorrect scientific information?

Lets start with the statement vaccines overstimulate the immune system. This statement is false; if we struck over from before stimulate we would have a true statement. The false statement, however, is rather unimposing and matter of fact. It also relies on a technical point about immune system biology. Perhaps if you saw it on Twitter or Facebook you would glance but not commit it to memory. If you were the parent of a two month old infant and in the process of thinking about your childs first immunizations, this bland statement might not influence you one way or the other.

Now lets change the tone of the statement. Every time you give your child one of the hundreds of vaccines we are told they have to have, her immune system goes wild with attack antibodies ready to destroy your babys health.

The substance of this new statement is largely the same as the first oneit asserts that somehow vaccines put the human immune system into overdrive. Yet it is now filled with many emotional words. There are now hundreds of vaccines that we are being told (i.e. coerced) into giving our children and they make the immune system go wild, attack, and destroy. Perhaps this statement, unlike the first one, grabs your attention and makes you wonder if indeed you want to vaccinate your baby.

Indeed, an impressive body of research shows that raising emotions, especially fear and anger, increases the chances that a false statement will be believed, remembered, and shared. As Portia puts it in Shakespeares The Merchant of Venice:

I can easier teach

twenty what were good to be done, than be one of the

twenty to follow mine own teaching: the brain may

devise laws for the blood, but a hot temper leaps oer

a cold decree. . . .

This is something politicians figured out long agodont just tell them that some people coming into your country may have committed crimes in the past; warn them that hordes of drug dealers, rapists, and terrorists are pouring over your borders ready to murder and pillage. If possible, find a single story of one such murderous immigrant and detail what happened to his victims in gory detail. When more sensible voices come by later and point out that the denominator for this phenomenonthe total number of people who have immigrated into your countryis far larger than the numeratorthe number of immigrants who commit crimesand that for the most part immigrants have a positive effect on your society and its economy, it is already too late. The original false, highly emotional message is now impervious to such corrective, data-filled recitations

People base their judgements of an activity or a technology not only on what they think about it but also on how they feel about it; they use an affect heuristic, writes Ohio State University Professor Ellen Peters, who studies the role of affect and emotions in decision-making.[1]For example, Peters explains, the terms mad cow disease and bovine spongiform encephalitis (BSE) refer to the same neurodegenerative disease, but media use of the former term elicits more fear and reduces beef consumption more than the latter.

What Determines the Things We Believe and Remember

We are bombarded with many, many more statements purporting to be factual than we can possibly incorporate into memory or on which to base decisions. Many times, we see statements about things thatwe have never considered before. Most likely, a young couple with a new baby did not spend much time thinking about vaccine safety until their own first baby approached two months old. Whether we notice a new statement in the media or on the internet depends in part, of course, on its relevance. The young couple is less likely to pay attention to a statement like to prevent dementia from getting worse, you should eat more vegetables than to one about how to prevent sudden infant death syndrome (SIDS).

Another important factor that determines what we believe and remember seems to be the novelty of a new statement. If a statement seems boring and already pass, we will ignore it. How many times can we be told get more exercise? That statement is absolutely true and critical for improving health and well-being, but put that way it fails to capture much attention.

If the exercise statement is couched with something that seems novel, however, we might stop and consider it. Exercise found in recent study to extend average life-span. We already knew that exercise is beneficial (or at least we have already been told that a million times), but here we have a brand-new piece of research that tantalizes us with the possibility of living longer. Adding a bit of novelty, even to an old message, makes it noteworthy. By the way, we made that headline up: although exercise is great, whether it extends how long one lives is dependent on a lot of factors. So please dont cite us and pass on a misstatement!

Perhaps the most important factor that determines how much impact a statement will make on decision-making is whether it evokes strong emotions when we first encounter it. In the simplified version of how our brains work, we have two systems, one fast and one slow. The fast one, which is based in the more primitive parts of the brain like the limbic cortex, uses short-cuts to make rapid decisions and is highly susceptible to basic emotions like fear, sadness, anger, disgust, and happiness. The slow one, which is based in the more sophisticated prefrontal cortex, uses reason and experience to make rational decisions based on data. These systems have the capacity to inhibit each other; when strong emotions are stirred the limbic cortex can inhibit the prefrontal cortex and prevent us from using reason to make a decision. On the other hand, we have the capacity to muster the power of the prefrontal cortex to suppress our more primitive brain and assert reason over emotion.

This view of the brain is a well-worn story that of course obscures a huge amount of detail and nuance, but it is useful in explaining why emotions are so important in reinforcing false beliefs. When the new parents see the emotional statement about the alleged dangers of vaccines, we would hope that they would pause, ask themselves if this could possibly be true, and consider what sources might give them reliable information. We want them to ask their own pediatrician and consult the websites of reliable organizations like the American Academy of Pediatrics or the CDC. In reality, however, this couple has a million things on its mindthere are constant recommendations about how to advance the babys diet, shes outgrowing her newborn clothes, people at work have stopped honoring the idea of maternity/paternity leave, emails and texts are mounting up, and the rent still has to be paid. There just isnt time to research vaccines.

But the terrifying statement about vaccines making the immune system go berserk has made its impression on the couple. It is not easy to ignore. So, they click on a few of the comments made in the Twitter feed or Facebook page where the statement is posted and see one comment after another that confirms the original scary message. Ten, twenty, thirty people jump into the conversation, each with some frightening tidbits of information about a child supposedly harmed by a vaccine or an easily graspable (albeit incorrect) explanation of how the immune system works and how vaccines harm it. Perhaps after 15 or 30 minutes of this, the couple realizes they have other things they must do and break away, but the damage has been done. They are emotionally aroused, scared, and a bit angry that it took a session on Twitter to find out things that the medical establishment and pharmaceutical industry are supposedly hiding from them.

In the worst-case scenario, this couple, that had previously entertained no fixed opinion about vaccinations, now decides to put off the babys first immunizations. Their child does not get her shots to prevent potentially catastrophic, communicable diseases like diphtheria, pertussis, tetanus, H. flu type b, and polio. Moreover, after this point even if the couple encounters correct information about vaccines, the mere mention of the word vaccine stimulates the original emotions they felt when they first saw that Twitter message and the reasoning parts of their brains immediately shut down. Who knows if this child, subsequent children the couple may have, or some of the children of people in their social network will ever get any vaccinations?

How to Counteract Misstatements

What can we do to prevent the initial contact with misinformation frombecominga fixed belief and influencingimportant health-related behaviors? As individuals, we can be on guard so that whenever we see a statement that provokes an emotional reaction, we push pause and wait to calm down before evaluating it.

Working on an individual level is important, but we also we need to develop strategies with a broader reach. One possibility is to make our corrective messages just as emotionally wrought as the misinformed ones. Instead of fact-based, unemotional explanations about how vaccinations work, why they are necessary, and how safe they arethe kind of messages that medical experts and scientists feel most comfortable givingwe might try showing pictures of babies wracked with whooping cough to the point that their ribs crack, dying from measles, or succumbing to H. flu meningitis. One of us has seen and taken care of children with illnesses that are now preventable with vaccines; it just takes one experience of a baby with diphtheria having a heart attack or a young child dying within hours of developing the rash of meningococcal meningitis to become passionate about immunizations. If you dont vaccinate your child, he or she could die, we might say in the spirit of stirring fear in the hearts of new parents.

A much discussed and very rigorously conducted study of this approach, however, yielded surprising findings that serve as a cautionary tale. In a randomized trial that varied the emotional content of correct information about vaccines, Dartmouths Brendan Nyhan and colleagues found that pictures of children sick with measles actually increased subjects belief in the false link between vaccines and autism.The researchers, and many others since then, speculated that this backfire effect occurred for much the same reason as explained above: any evocation of emotion, regardless of its content, summons memory of the original belief rather than the newly presented correct one. From this study, many have decided that counteracting emotionally driven health misinformation with emotionally driven correct information is potentially dangerous.

Since the publication of this paper nearly six years ago, some studies have replicated the Nyhan et al finding, but others have not supported the backfire effect." Thus, whether fighting fire with fire (i.e.,emotional misinformation with emotional correct information) is an effective or even safe intervention is going to require more research.

One way of counteracting false health and science information without risking a putative backfire effect might be to prevent it from being committed to permanent memory in the first place. The literature is replete with warnings that merely counteracting false statements with facts is an ineffective approach and that people cannot be counted on to use their analytical skills when confronted with misstatements. Yet studies are increasingly showing that neither of these is absolutely the case and that people can be encouraged to use analytical thinking to make decisions, even with regard to controversial topics. In fact, findings suggest that it is precisely leaving false statements uncorrected that leads to their being nearly impossible to dislodge later on. Therefore, media and policymakers should ensure that the coverage of misinformation at no point presents itself without corrective information, assert psychologists Man-pui Sally Chan, Christopher Jones, and Dolores Albarracin.[2] Uncorrected repetition of misinformation opens the opportunity to generate thoughts in agreement with it.

The Elements of Counteracting Misinformation

The critical elements to help ensure that corrective information works seem to involve at least three things. First, corrections should be made as close in time as possible to misstatements. Second, corrections should appear on the same platform as the misstatements. Third, corrections should be clear, understandable, and appeal to the values of the audience.

We know from abundant basic and clinical neuroscience that short-term memories are malleable but become much less so when transferred to long-term memory storage. We also know that place plays an important part in memorywhere we saw or experienced something is an important way in which memories are stored and retrieved. From this information, it seems probablebut still to be testedthat our first two assertions are accurate: to successfully counteract a misstatement, place the correct information close to it in both time and place. That means, therefore, we should try to get our scientific statements directly onto the Twitter feeds, Facebook group pages, and other social media platforms and websites as soon as misstatements appear on them.

The third proposed basic element for counteracting misinformation is less easily justified. The literature on the form that corrective information should take is too long to review here, but much of it is laboratory based and it is therefore unclear what will really work in the field. Although it is clear that strong emotion fosters memory, including memory of false statements, we will begin by steering clear of trying to evoke fear and anger in case the backfire effect is a real phenomenon. Rather, we hope to focus on people like ourprototypical couple who has just read the frightening message about vaccine safety just as they are about to decide on whether to vaccinate their new child. With that couple in mind, we will approach counteracting messages by trying to establish common interests, inquiring about what the people already know about the topic, and gently introducing facts in ways that are understandable but not overly simplified.

Is it necessary to scare people in order to get them to shun false statements and adopt healthy behavior? Or does that backfire and make them even more recalcitrant to scientific consensus? We know quite a lot about this from laboratory studies. Nowits time to find out what works on everyones favorite social media platform.

Read the original post:
Frighten Them and They Will Believe It - Psychology Today

Read More...

Stonyfield Organic Yogurt Introduces The First Organic Daily Probiotic Yogurt Drink On The Market – The Laconia Daily Sun

Monday, January 13th, 2020

LONDONDERRY, N.H., Jan. 13, 2020 /PRNewswire/ -- Stonyfield Organic, the country's leading organic yogurt maker, announced today the launch of Daily Probiotics, a probiotic yogurt drink in a 3.1oz easy-to-drink format designed to support both immune and digestive health.* Available in two flavors, Blueberry Pomegranate and Strawberry Acai, the new Daily Probiotics are made with real fruit and organic low fat milk, all for only 60 calories. Stonyfield's latest innovation comes as the increasing consumer interest in preventive daily healthcare continues to fuel demand for convenient products made with probiotics, with the global probiotics market predicted to reach nearly 80 billion dollars by 2025.1

"Our new Daily Probiotics are a delicious snack that also provide billions of live active cultures in a portable, on-the-go format," said Sophie Schmitt, Stonyfield Organic Brand Director. "We understand that consumers are looking for snacking options that serve multiple purposes at once and our Daily Probiotics do just that offering both excellent taste and quality ingredients as well as probiotics to support immune and digestive health in one convenient bottle."

"Beyond the standard cultures that are required, you may be surprised to learn that many yogurts actually do not contain the probiotic cultures that help support your immune system health," said Maya Feller, RD. "Studies have shown that eating yogurt rich in probiotics can help foster the beneficial gut bacteria that support an improved immune system by possibly increasing white blood cell counts, so it's important to look for yogurts that include these specific strains."

Daily Probiotics shots are USDA Organic, Non-GMO Project Verified and Gluten-Free. Daily Probiotics shots are available in the yogurt aisle of retailers nationwide in a 3.1oz. 6-pack format for a suggested retail price of $4.49. For more information visit stonyfield.com.

* When eaten regularly as part of a healthy diet and lifestyle.

1Grand View Research, Inc.

About Stonyfield OrganicAs the country's leading organic yogurt maker, Stonyfieldtakes care with everything it puts into its products and everything it keeps out. By saying no to toxic persistent pesticides, artificial hormones, antibiotics and GMOs, Stonyfield has been saying yes to healthy food, healthy people, and a healthy planetfor 36 years. Stonyfield, a Certified B-Corp, is also helping to protect and preserve the next generation of farmers and families through programs like its Direct Milk Supply and Wolfe's Neck Organic Training Program as well as StonyFIELDS,a nationwide, multi-year initiative to help keep families free from toxic persistent pesticides in parks and playing fields across the country.

See original here:
Stonyfield Organic Yogurt Introduces The First Organic Daily Probiotic Yogurt Drink On The Market - The Laconia Daily Sun

Read More...

Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals – Business Wire

Monday, January 13th, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today highlighted recent progress across several programs and outlined goals for 2020. These updates will be discussed during a webcast presentation at the 38th annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 11:30 a.m. PT (2:30 p.m. ET).

In 2019 we generated landmark data from our ADC-based targeted patient preparation platform, which is delivering a new class of antibody-drug conjugates (ADCs) that have the power to bring one-time treatment to more patients with autoimmune diseases, blood cancers and genetic diseases. We also presented clinical data for our first-line stem cell mobilization program, MGTA-145, which we are developing as the new standard of care for stem cell mobilization with the potential to benefit all of the transplant-eligible patients each year, said Jason Gardner, D. Phil., President and Chief Executive Officer, Magenta. As we begin 2020, we are particularly excited to unveil our MGTA-117 clinical candidate for targeted patient preparation for stem cell transplant or gene therapy. New results announced today highlight the potency, safety and broad therapeutic index of MGTA-117, well above that of currently approved ADCs. We believe that MGTA-117 is the optimal agent for depleting stem cells to enable safe immune reset. We look forward to moving this program into the clinic with initial clinical data expected in 2021.

Targeted Patient Preparation Programs

Current methods to condition patients before transplant and gene therapy are dependent on toxic, non-specific chemotherapy or radiation. These pre-transplant treatments are associated with significant side effects, including infertility, cancer, organ damage and death. Magenta is developing targeted, disease-modifying ADCs that are designed to precisely and rapidly remove the disease-causing cells in the body and enable immune system reset without the need for chemotherapy or radiation.

CD117-ADC Recent Progress

Data presented at the American Society of Hematology (ASH) annual meeting in December 2019, showed the first-ever successful transplant of gene-modified cells in non-human primates using a CD117-targeted, single-agent ADC from Magenta, without the use of chemotherapy or radiation. These unprecedented results validate and advance Magentas conditioning platform.

Building on this work, Magentas new clinical candidate, MGTA-117, is a CD117 antibody conjugated to amanitin. Results published today in an abstract for the Transplant and Cellular Therapy annual meeting show that MGTA-117 potently depleted stem and progenitor cells and demonstrated a wide tolerability: potency ratio of 30 fold (therapeutic index; typical range for approved ADCs at this stage is two to six fold). This program is advancing to the clinic and further validates Magentas antibody drug conjugate-based conditioning platform. MGTA-117 was developed under a partnership with Heidelberg Pharma that grants Magenta exclusive worldwide development and marketing rights for ADCs using an amanitin payload and targeting CD117.

MGTA-117 in 2020

Magenta is scaling up manufacturing of MGTA-117 and completing IND-enabling studies in 2020. The Company intends to move this new product candidate into the clinic with initial clinical data expected in 2021.

CD45-ADC Recent Progress

Current standard treatment for patients with multiple sclerosis involves years of chronic dosing of medications that do not halt the progression of the disease. For patients with systemic sclerosis, a potentially fatal autoimmune disease, there are no approved therapies. Immune reset through stem cell transplant has demonstrated durable remissions in thousands of patients with autoimmune diseases such as multiple sclerosis and systemic sclerosis, and it is recommended by the European League Against Rheumatism (EULAR) in treatment guidelines for systemic sclerosis. The immune reset process involves two main steps: removing the disease-causing cells and replacing them with healthy cells to rebuild the immune system to a healthy state.

Magenta is developing targeted ADCs designed to precisely remove the disease-causing cells in the body without the need for chemotherapy or radiation. Magentas CD45-ADC program targets CD45, a protein expressed on immune cells and stem cells and is designed to remove the cells that cause autoimmune diseases in order to enable curative immune reset.

Data presented at the American College of Rheumatology (ACR) meeting in November 2019 showed that a single dose of CD45-ADC removed disease-causing reactive T cells, enabled successful immune reset and rebuild of the immune system and was well tolerated in three models of autoimmune disease, including the EAE model, the most reliable murine model of multiple sclerosis. Further, a single dose of CD45-ADC significantly reduced disease incidence and delayed disease onset in this model that has successfully provided preclinical proof of concept for many clinically validated standard-of-care therapies.

CD45-ADC in 2020

Magenta has identified a lead antibody and has progressed this program into IND-enabling studies, which the Company plans to further advance in 2020.

MGTA-145 First-Line Stem Cell Mobilization Therapy

MGTA-145 Recent Progress

Magenta is developing MGTA-145 as the new first-line standard of care for stem cell mobilization in a broad range of diseases, including autoimmune diseases, blood cancers and genetic diseases. MGTA-145, a CXCR2 agonist, works in combination with plerixafor, a CXCR4 antagonist, to harness the physiological mechanism of stem cell mobilization.

Magenta is currently studying MGTA-145 and plerixafor in a Phase 1 study in healthy volunteers. Data from the Phase 1 study presented at the ASH annual meeting in December 2019 showed that MGTA-145 in combination with plerixafor successfully enables safe, same-day dosing, mobilization and collection of sufficient high-quality hematopoietic stem cells for transplant. Further, when cells collected from the first two apheresis subjects were transplanted into humanized mice, the cells engrafted more rapidly and at a five-fold higher level than cells from G-CSF-mobilized peripheral blood.

MGTA-145 in 2020

Magenta intends to complete the Phase 1 study and move this program into multiple Phase 2 studies in patients in 2020. The Phase 2 studies will include both allogeneic and autologous transplant settings and will evaluate mobilization and collection of high-quality cells and engraftment of the cells after transplant.

MGTA-456 Cell Therapy

MGTA-456 Recent Progress

MGTA-456 is a cell therapy designed to provide a high dose of stem cells that are well matched to the patient to enable safe immune and blood system rebuild and durable remissions in patients with blood cancers. In September, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for MGTA-456 for the treatment of multiple inherited metabolic disorders.

Magenta is currently studying MGTA-456 in a Phase 2 study in patients with inherited metabolic disorders, including cerebral adrenoleukodystrophy (cALD) and Hurler syndrome. These are rare, rapidly progressive neurologic disorders that are fatal when left untreated. Results in the first two evaluable patients with cALD updated in December 2019 showed early and durable resolution of the disease at 12 months follow-up. The Loes score and NFS score, which measure progress of the disease, remained stable, suggesting that progress of the disease has been halted in these patients. The early and durable resolution of disease with MGTA-456 is not consistently seen with other therapies, including standard stem cell transplant, gene therapy or enzyme replacement therapy.

MGTA-456 in 2020

Magenta intends to complete enrollment in the Phase 2 in 2020 and continue dialogue with the FDA under the RMAT designation, and to discuss with the European Medicines Agency (EMA) for development in Europe

About Magenta Therapeutics

Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K, as updated by Magentas most recent Quarterly Reports on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Original post:
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals - Business Wire

Read More...

Page 39«..1020..38394041..5060..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick